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Summary The effect of tamoxifen upon cellular DNA ploidy in carcinoma of the breast was assessed by
flow cytometry (FCM), in a prospective group of 77 patients with primary operable disease. Each had a
needle biopsy at the outpatient visit for diagnosis and FCM analysis, and definitive surgery was performed a
median of 8 days later. Forty received tamoxifen during this period - 40mgqds loading dose for 24h,
followed by 20mg daily until the day of operation: 37 patients received no therapy. The DNA histogram
from the needle biopsy was compared with that obtained from the resected tumour for each individual. There
was little change between the pair of histograms from tumours from the untreated patients. In those who had
received tamoxifen the most consistent effect was a marked reduction in the magnitude of the 'tetraploid'
peak in tetraploid or near-tetraploid tumours with DNA indices 1.8-2.0. There was little change in diploid or
'other DNA-aneuploid' tumours. In tetraploid tumours (DNA index of 2.0) the percentage of nuclei in the
diploid S phase was significantly related to the percentage of nuclei in the diploid G2+M/tetraploid Gl peak
(P<0.003, unpaired t test). These data suggest that an effect of tamoxifen can be demonstrated by FCM
upon tumours exhibiting a tetraploid or near-tetraploid DNA content. It is possible that tetraploid or near-
tetraploid human mannary tumours may be a distinct group of endocrine responsive tumours within the
overall group of aneuploid tumours, and that the majority are probably derived from the diploid population
rather than being a true aneuploid population.
It is well established that well-differentiated carcinomas
generally have a better prognosis than poorly-differentiated
tumours of comparable stage. Flow cytometry (FCM) has
been used in many studies to evaluate differentiation by
means of estimating cellular DNA ploidy, but the findings
from reports which compare diploid tumours with the total
aneuploid group are confusing (Moran et al., 1984; Kute et
al., 1985; Stuart-Harris et al., 1985). There is presently little,
if any, utility for flow cytometry in the clinical management
of carcinoma of the breast. In the preceding paper we have
reported that patients with advanced carcinoma of the breast
who had diploid or 'tetraploid' tumours, fared better than
those with 'other DNA-aneuploid' tumours (Baildam et al.,
1987). This benefit was manifested in a significantly higher
rate of response to endocrine treatment, a significantly
longer time to progression whilst on therapy, and a longer
period of survival after the start of endocrine therapy.
Response to treatment is probably dependent to an extent
on cell cycle kinetics, which may be evaluated by DNA
ploidy estimation (Fossa et al., 1984). Some data derived
from experimental studies indicate that changes in DNA
histograms may occur after hormonal manipulation
(Osborne et al., 1983; Sutherland et al., 1983; Brunner et al.,
1983). The aim of this prospective study was to investigate
whether any effect of tamoxifen in vivo could be demon-
strated on the DNA histograms derived from primary
human mammary carcinomas.
Patients and methods
Patients
This study was carried out on patients who presented to the
breast clinic at the University Hospital of South Manchester
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with a primary operable carcinoma of the breast over a
twelve month period from 1984 to 1985 (n=77). A Trucut
needle biopsy was performed on each patient for confir-
mation of diagnosis at the first visit; and arrangements were
made for individual hospital admissions for definitive
surgery, wherever possible the following week. Forty patients
were then given tamoxifen 40mgqds for one day (loading
dose) followed by 20mg each day until the day of operation,
a median of 8 days later: 37 were controls and were given no
therapy in the period between biopsy and operation. The
original aim of this study was to demonstrate any possible
effect of tamoxifen on the concentrations of progesterone
receptor within each tumour; this was explained to every
patient and consent was obtained. The clinical characteristics
for the patients are listed in Table I.
A portion of tumour from needle biopsies as well as
resected tumours was stored in liquid nitrogen for
subsequent receptor assays.
Flow cytometry
Paraffin-embedded, formalin-fixed material was used
throughout. Sections were taken from adjacent areas on the
blocks for confirmation of histopathological diagnosis. In
Trucut biopsies 3 or 4 sections of 30,um thickness were used
to ensure sufficient numbers of nuclei for analysis. Single
30,um sections were used from the resected samples. Nuclear
suspensions for FCM analysis were prepared by the method
of Hedley, but with a slight modification of the fluoro-
chrome. We used propidium iodide whereas the published
method employed DAPI (Hedley et al., 1983). Samples of
tumour were dewaxed twice for 10min in xylene, then
rehydrated in reducing concentrations of ethanol (100%,
95%, 70%, 50%) and washed in tris-buffered saline, (TBS),
for 10min. The rehydrated sections were incubated for 1 h in
RNase (Sigma Co.) at a concentration of 1 mgml-1, then
exposed for 30min to 0.5% pepsin adjusted by HCl to
pHl.5. Release of nuclear particles was improved by vortex
mixing or by gentle repeated aspiration. Suspensions were
centrifuged for 15min and pellets resuspended after filtration
through nylon mesh in propidium iodide staining solution
(0.05mgml-1 in 1.12% sodium citrate). Measurements were
obtained from a Cytofluorograph Model 4800A (Biophysics
System Inc, Mahopac, New Jersey, USA) with argon laser
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interfaced to a Hewlett-Packard 9845A Desk Top Computer.
5,000 nuclear particles were measured from each sample.
Analysis ofhistograms
Half peak coefficient of variability (CV) was evaluated for
each histogram and ranged from 2-9% (median 5%).
Analysis was repeated for any histogram with a CV greater
than 10%. For the description of aneuploid peaks, DNA
indices were used, calculated as the ratio of the aneuploid
peak channel to the first peak, which was considered to be
diploid or near diploid and was present on each histogram
(Coulson et al., 1984). Diploid tumours were defined by
DNA index 1.0-1.1, tetraploid tumours by a diploid
G2 +M/tetraploid G1 >10% nuclei analysed, together with a
tetraploid G2+M peak. Histograms were grouped together
as diploid (DNA index 1.1), 'tetraploid' (near-tetraploid
with DNA index 1.8-1.9, and tetraploid with DNA index
2.0), and 'other DNA-aneuploid' (DNA indices 1.2-1.7, and
.2.1). In multiploid tumours each peak was defined by its
own DNA index and the greatest one used for the overall
analysis. For calibration of the cytofluorograph normal
human peripheral blood lymphocytes, fixed in 95% ethanol,
and paraffin-embedded tonsils were used. These gave com-
parable fluorescence for diploid histograms. The ethanol-
fixed lymphocytes displayed slightly greater fluorescence.
Histogram analysis was undertaken without knowledge of
either the patient or treatment category.
The number of nuclei represented in each histogram peak
was estimated by a MOPP Videoplan graphic tablet
program. Five thousand nuclear particles were counted for
each histogram, and the number in each peak calculated
from proportional areas. The diploid S phase and G2M
fractions in 49 DNA histograms which had tetraploid DNA
peaks (DNA index 2.0) were analysed by well recognised
methods of computation (Dean et al., 1983; Blackledge et
al., 1980).
Steroid hormone receptor assays
Tissue from needle biopsies and from resected tumours
removed at operation were stored in liquid nitrogen until the
time of receptor assay. Each frozen sample was homogenised
by means of a teflon capsule and tungsten ball which had
both been pre-cooled with liquid nitrogen, and subjected to
the action of a dismembranator for 30 sec. The resulting
powder was suspended in buffer (10mM Tris-HCl pH 7.4
with 1mM EDTA, 0.5mM dithiothreitol and 30% v/v
glycerol), and centrifuged at 1,000g for 10min at 4°C to
remove nuclei, fat, and any debris.
For all samples the method of isoelectric focusing (IEF)
was employed (Lloyd et al., 1982; Harland et al., 1983). Any
positive value with an appropriate isoelectric point (pl) was
taken to indicate a positive receptor value. The total protein
content was measured by the BCA protein assay reagent
(Pierce UK Ltd., Cambridge, UK).
Tamoxifen estimations
As a check that patients were taking tamoxifen, a preopera-
tive blood sample was taken for assay of serum tamoxifen
concentrations. This was performed by means of a modi-
fication of a previously published method (Golander &
Sternson, 1980). The mean serum tamoxifen level pre-
operatively was 87.9 ngml 1, range 23.7-176.4 ngml-.
Statistical methods
All evaluations were made by the Chi-squared and Fisher's
Exact tests.
Results
The paraffin-embedded Trucut needle biopsy cores provided
consistently good tissue for analysis. The proportions of
DNA ploidy groups in histograms from the Trucut biopsies
for all 77 patients were compared with the findings for
tumours from patients with advanced disease in the study
described previously (Table II), (Blaildam et al., 1987). The
proportion of 'other DNA aneuploid' tumours was 28% for
both studies. There was a higher incidence of tumours with
a DNA content of 'tetraploid' in the needle biopsies (44%)
than was found in the previous study (34%), and this was
reflected in the lower incidence of diploid tumours.
The findings in the Trucut biopsies of patients who were
destined to receive tamoxifen were very similar to those
found in samples from patients who were not. (Table III).
In patients who received no treatment with tamoxifen the
findings in the resected tumour were essentially similar to
those in the Trucut biopsies. The number of nuclear particles
in the diploid G2+M or second major peak in each Trucut
biopsy, was compared with the number on that same peak
from the analysis of its resected tumour. There were some
minor differences (Figure 1). One diploid tumour produced a
significant 'tetraploid' peak in the second sample (diploid
'G2+M'>10% of total cell population, plus a tetraploid
G2+M peak), and there were minor changes in 'other
DNA-aneuploid tumours. When tumours with 'tetraploid'
DNA content were considered there were differences
apparent between the Trucut biopsies and the resected
Table I Clinical details of patients for DNA ploidy analysis.
Tamoxifen Rx Controls
n=40 n=37
Age range 43-84 years 35-77 years
median 63 years 60 years
Tumour size
mean 4.03 cm 3.02cm
range 1.0-11.0cm 1.0-7.0cm
Post-menopausal 30 (75%) 29 (78%)
Histopathology
Infiltrating duct carcinoma 30 (75%) 28 (76%)
Infiltrating lobular carcinoma 9 (22%) 6 (16%)
Other 1 (3%) 3 (8%)
Receptor status on first tumour sample
ER+ 24 (63%) 18 (52%)
PR+ 16 (42%) 13 (37%)
N/K 2 2
Table II DNA ploidy - comparison between Trucut biopsies on
primary tumours and the study in advanced disease.
Trucut biopsies Advanced study
n=77 n=136
Diploid tumours 20 (27%) 52 (38%)
'Tetraploid' tumoursa 36 (44%) 46 (34%)
'Other DNA-aneuploid"b 21 (28%) 38 (28%)
P=NS
aDNA index 1.8-2.0; bDNA index 1.2-1.7, and >2.1.
Table III DNA ploidy - Trucut samples.
Before tamoxifen No tamoxifen
n=40 n=37
Diploid tumours 10 (26%) 10 (27%)
'Tetraploid tumours'a 20 (48%) 16 (43%)
'Other DNA aneuploid"b 10 (26%) 11 (30%)
P=NS
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Figure 1 Changes in the number of nuclei in G2/M or second
major peaks between pairs of tumours not treated with
tamoxifen. Each pair of tumours is represented by a single line.
tumours. In 6 tumours the number ofnuclei in the 'tetraploid'
peak increased, in 4 it decreased, and in 5 it remained the
same. But these differences failed to achieve statistical
significance.
In patients treated with tamoxifen the results were similar
for diploid and 'other DNA-aneuploid' tumours. When
tumours with 'tetraploid' DNA peaks were considered there
were changes between the two histograms. In these patients
there was a striking difference between the 'tetraploid' peaks
obtained from the needle biopsy and those from the resected
tumours, and an example of the change is shown (Figure 2).
The 'tetraploid' peak was greatly diminished in a majority
of tumours, and 15 of the 20 tumours were of diploid
histogram pattern in the second sample (Figure 3). These
differences were highly significant (Chi-square =20.97,
P<0.000).
The number of nuclei in the diploid G2 +M or second
major peak in each resected tumour, was expressed as a ratio
to the same peak in the Trucut biopsy (Figure 4). In patients
who had not received tamoxifen the median ratios for all
three tumour groups were around unity, reflecting minimal
change only between each pair of samples. For patients who
had received tamoxifen, the median ratios for diploid and
'other DNA aneuploid' tumours were also around unity. In
the tumours with a 'tetraploid' peak treated with tamoxifen
there was median ratio of 5, reflecting the decrease in the
'tetraploid' peaks. Twelve of the fifteen originally 'tetraploid'
tumours which became diploid in the resected tumour were
positive for ER and for PR (Figure 5). Two 'tetraploid'
tumours in the group which was not treated with tamoxifen
also become diploid in the resected specimen. Both were
positive for ER and for PR. There was a very low incidence
of receptor positivity within the 'multiploid' tumours - 3 of
10 were ER positive, and 1 of 10 was PR positive.
Diploid S phasefraction and 'tetraploid' peaks
The diploid S phase fraction in 40 tumours with a DNA
index of 2.0 was estimated by means of a computer program
which is in wide use (Fried, 1976; Blackledge et al., 1980).
The diploid S phase fraction was related to the number of
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Figure 2 Changes in the DNA histogram after tamoxifen in a
tumour with a tetraploid population ofcells.
nuclei in the diploid G2+M/tetraploid Gl peak for tumours
derived both from the advanced study and also from the
needle biopsies of the primary operable study. The number
of nuclei in the diploid S phase fractions and in the
G2+M/tetraploid GI peaks were highly correlated (P<
0.003, unpaired t test). The increase in the mean diploid S
phase in shown with increase of the G2+M/tetraploid GI
peak relative to the diploid GI peak in DNA histogram
patterns (Figure 6). For this calculation the 40 histograms
have been supplemented with 9 histograms from tetraploid
colonic tumours.
Discussion
Trucut biopsy samples provided adequate tissue for DNA
ploidy analysis by flow cytometry: two or three 30 um
sections were taken from each sample and it was not difficult
to obtain 5,000 nuclei after dissociation of the tissue. It has
been estimated that a single 30pm section of tissue 1 cm2 can
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Figure 3 Changes in the number of nuclei in G2/M or second
major peaks between pairs of tumours treated with tamoxifen.
Each pair of tumours is represented by a single line.
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Figure 4 Ratios of number of nuclear particles in G2/M or
second major peaks from resected tumours compared with needle
biopsies in tumours not treated with tamoxifen.
Receptor status is shown.
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yield up to 5 x 106 nuclei (Coon et al., 1986). Thus an
average trucut sample (2 x 0.2 x 0.1 cm) could release
2.5 x I05 nuclei from one 30pgm section.
Tamoxifen was given as a loading dose so that therapeutic
levels were present at the time of operation, and this was
confirmed by measurement of serum drug concentration.
The difficulty of interpretation of a 'tetraploid' peak has
been discussed in the preceding study (Baildam et al., 1987).
We found no consistent effect of tamoxifen on diploid and
'other DNA-aneuploid' tumours, but in 'tetraploid' tumours
(near-tetraploid and tetraploid) with a significant 'tetraploid'
peak (_ 10% nuclei), after tamoxifen in the majority there
was a highly significant reduction in the number of nuclei in
the 'tetraploid' peak. The possibility that the difference
between the two samples might result from heterogeneity of
the tumours must be considered, but this seems unlikely
because no consistent changes were found in those which
were untreated. In previous studies variations in DNA
content were not found between primary tumours and
axillary metastases (Auer et al., 1984; Erhardt & Auer,
1986a). Variations within tumours were present in one study
in two of eight tumours when multiple biopsies were taken
(Prey et al., 1985), and in another report, in two of seventeen
tumours (Erhardt & Auer, 1986b). It seems unlikely that the
reduction of the 'tetraploid' peaks in this study could have
resulted from other than a direct or indirect effect of
tamoxifen.
This study emphasises the difficulty of interpretation of
'tetraploid' DNA peaks. It is impossible to distinguish by
flow cytometry between the relative contribution of diploid
G2+M and tetraploid GI nuclei to the peak. It may be
postulated that many tumours with apparent 'tetraploid'
peaks are essentially diploid tumours with a high proportion
of cells partially arrested in the G2+M phases of the cell
cycle. These 'tetraploid' cells, if generated from diploid or
near-diploid cells, could represent highly dynamic and
therefore potentially therapeutically-sensitive cell
populations. However, it is also conceivable that in some
tumours, the 'tetraploid' population consists of non-
malignant cells (such as adjacent duct epithelium and/or
stromal cells) with a high G2M. Inhibition of cell-cycle
progression by tamoxifen in Gl (or early G2) would allow
the 'tetraploid' population of cells to pass either through
mitosis and enter the apparent diploid population, or to die
(Taylor et al., 1983a; Brunner et al., 1985). One study
demonstrated that 'tetraploid' peaks in histograms obtained
from oestradiol-synchronised MCF-7 cell lines, diminished
dramatically after the cultures had been exposed to tamoxi-
fen for sixteen hours (Sutherland et al., 1984). The cor-
relation between the proportion of cells in diploid S phase
and G2+M in tetraploid tumours with a DNA index of 2.0
supports this suggestion. Further experimental evidence for a
diploid-tetraploid interdependence and induced diploid poly-
ploidisation has been reported in cycling cell populations
treated with cytostatic agents (Tobey et al., 1978).
The reason for the postulated block in G2 is not clear.
Administration of oestradiol to immune-deprived mice who
bear the T61 human mammary cell line results in cessation
of tumour growth and a dramatic increase in the number of
cells in diploid S and G2+M, and a concurrent increase in a
tetraploid S and G2+M, described as 'polyploidisation'
(Brunner et al., 1983). It is possible that the 'tetraploid'
peaks could be produced by the effect of endogenous
oestradiol causing accumulation in G2: such an accumu-
lation could be reversed by tamoxifen. Furthermore the
tetraploid G2+M peaks could be the result of 'polyploid-
isation' of diploid cells.
The diminution of the 'tetraploid' peak in response to
tamoxifen is consistent with most of these tumours being
endocrine responsive. This hypothesis is supported by the
demonstration that patients with advanced disease had a
high probability of response to tamoxifen if their primary
tumour contained a 'tetraploid' peak (Baildam et al., 1987).
However, it should be noted that tamoxifen has
oestrogenic, as well as antioestrogenic effects in the first few
weeks of treatment, which account for flare reactions
observed clinically. Oestrogens have been found to produce
cell cycle effects in breast cancer patients which are
apparently independent of receptor status and perhaps
mediated indirectly via an effect on host cells (cf. Conte et
al., 1985; Haslam, 1986).
When the diploid G2+M was <10%, there was no
detectable effect of tamoxifen upon the S or G2 phases of
diploid tumours. It is possible that in diploid tumours
tamoxifen may inhibit proliferation by an effect in both Gl
and G2. This has been suggested previously for MCF-7 cells
treated with tamoxifen in vitro, and in the T61 tumours
grown in immune-deprived mice (Brunner et al., 1983;
Lykkesfeldt et al., 1984; Osborne et al., 1983).
It cannot be determined at this stage whether clinical
response to therapy corresponds to changes in the DNA
histograms. Indeed the effect reported here may be
completely independent of clinical response and the
mechanisms whereby response is produced. We can only
reiterate that in our study on advanced disease patients with
'tetraploid' tumours did demonstrate the highest response
rates to endocrine manipulation, and did fare better than
those with 'other DNA-aneuploid' tumours. The series of
patients with primary operable disease is being closely
monitored and more information will become available in
time with regard to relapse and response to systemic
treatment.
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